From: Physical activity and telomere length in early stage breast cancer survivors
 | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
OR (95% CI) | P | AOR (95% CI) | P | |
Demographic characteristics | Â | Â | Â | Â |
Age, years | Â | Â | Â | Â |
  <55 (reference) | 1 |  | 1 |  |
  55 to 65 | 1.33 (0.61, 2.92) | 0.48 | 0.96 (0.38, 2.41) | 0.91 |
  >65 | 2.62 (1.21, 5.65) | 0.01 | 1.44 (0.52, 4.00) | 0.48 |
BMI | Â | Â | Â | Â |
  <25 (reference) | 1 |  | 1 |  |
  25 to 30 | 1.47 (0.74, 2.94) | 0.27 | 1.32 (0.59, 2.91) | 0.50 |
  >30 | 3.03 (1.58, 5.81) | <0.001 | 1.93 (0.88, 4.23) | 0.10 |
Race/ethnicity | Â | Â | Â | Â |
  White (reference) | 1 |  | 1 |  |
  Non-white* | 3.81 (2.11, 6.86) | <0.001 | 2.29 (1.07, 4.90) | 0.03 |
Educational level | Â | Â | Â | Â |
  High school or less (reference) | 1 |  | 1 |  |
  College | 0.43 (0.23, 0.80) | 0.007 | 0.34 (0.16, 0.70) | 0.003 |
  Graduate or higher | 0.18 (0.09, 0.40) | <0.001 | 0.20 (0.08, 0.47) | <0.001 |
Marital status | Â | Â | Â | Â |
  Married/partnered (reference) | 1 |  | 1 |  |
  Single | 2.57 (1.50, 4.40) | <0.001 | 1.52 (0.77, 3.00) | 0.25 |
Previous chemotherapy | Â | Â | Â | Â |
  No chemotherapy (reference) | 1 |  | 1 |  |
  Chemotherapy | 0.50 (0.29, 0.86) | 0.01 | 0.81 (0.40, 1.63) | 0.55 |
Current aromatase inhibitor | Â | Â | Â | Â |
  None (reference) | 1 |  |  |  |
  Letrozole | 0.98 (0.30, 3.21) | 0.97 |  |  |
  Anastrozole | 1.75 (0.65, 4.71) | 0.27 |  |  |
  Exemestane | 1.14 (0.32, 4.05) | 0.84 |  |  |
Cormorbid conditions | Â | Â | Â | Â |
  None (reference) | 1 |  | 1 |  |
  One | 1.14 (0.44, 2.97) | 0.78 | 1.11 (0.34, 3.49) | 0.88 |
  Two or more | 2.06 (0.88, 4.83) | 0.10 | 1.71 (0.57, 5.05) | 0.34 |
Anxiety | Â | Â | Â | Â |
  Normal (reference) | 1 |  |  |  |
  Sympomatic | 0.92 (0.49, 1.70) | 0.79 |  |  |
Depression | Â | Â | Â | Â |
  Normal (reference) | 1 |  | 1 |  |
  Symptomatic | 3.28 (1.53, 7.06) | 0.002 | 4.57 (1.86, 11.25) | <0.001 |